The engineered protein 3K3A-APC, a variant of activated protein C, is in clinical trials for stroke and has demonstrated neuroprotective effects in animal models of other neurological diseases as well. Now, researchers from the University of Southern California have found that 3K3A-APC was effective at preventing behavioral deficits and neuronal damage in an animal model of Alzheimer's disease (AD).